Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Spero Therapeutics, Inc. SPRO
$1.83
-$0.09 (-4.69%)
На 18:01, 12 мая 2023
+446.45%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
98892351.00000000
-
week52high
3.18
-
week52low
0.68
-
Revenue
-4930000
-
P/E TTM
0
-
Beta
0.86989600
-
EPS
-1.26000000
-
Last Dividend
0.16500000
-
Next Earnings Date
15 мая 2023 г. в 10:59
Описание компании
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 23 мая 2022 г. |
| Berenberg | Hold | Buy | 20 мая 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 17 мая 2022 г. |
| Evercore ISI Group | In-Line | Outperform | 04 мая 2022 г. |
| Evercore ISI Group | Outperform | In-Line | 23 сент 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 26 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| JOSEPH TAMARA L | D | 324644 | 3394 | 02 февр 2023 г. |
| Keutzer Timothy | D | 327144 | 3394 | 02 февр 2023 г. |
| Shukla Sath | D | 312517 | 9504 | 02 февр 2023 г. |
| JOSEPH TAMARA L | A | 328038 | 265957 | 01 февр 2023 г. |
| Keutzer Timothy | A | 330538 | 265957 | 01 февр 2023 г. |
| Mahadevia Ankit | A | 810118 | 531914 | 01 февр 2023 г. |
| HAMED KAMAL | A | 475957 | 265957 | 01 февр 2023 г. |
| Shukla Sath | A | 322021 | 265957 | 01 февр 2023 г. |
| VINK PATRICK V.J.J. | A | 15471 | 15471 | 03 янв 2023 г. |
| Tregoning Kathleen | A | 30943 | 30943 | 03 янв 2023 г. |
Новостная лента
Spero Therapeutics, Inc. (SPRO) Q1 2023 Earnings Call Transcript
Seeking Alpha
11 мая 2023 г. в 20:59
Spero Therapeutics, Inc. (NASDAQ:SPRO ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Ted Jenkins – Vice President, Investor Relations and Strategic Finance Ankit Mahadevia – Chief Executive Officer Sath Shukla – Chief financial Officer Kamal Hamed – Chief Medical Officer Conference Call Participants Louise Chen – Cantor Ritu Baral – TD Cowen Gavin Clark-Gartner – Evercore ISI Boobalan Pachaiyappan – H.C. Wainwright Operator Good afternoon, and welcome to the Spero Therapeutics First Quarter 2023 Financial Results Conference Call.
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
11 мая 2023 г. в 19:02
Spero Therapeutics, Inc. (SPRO) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.01 per share a year ago.
Spero Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
GlobeNewsWire
04 мая 2023 г. в 08:05
CAMBRIDGE, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Thursday, May 11, 2023 at 4:30 p.m. ET to report its first quarter 2023 financial results and provide an update on its business and pipeline.
Spero Therapeutics to Present at Upcoming Investor Conference
GlobeNewsWire
26 апр 2023 г. в 08:05
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Spero's management team will present and be available for one-on-one meetings at the H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York City, on May 2, 2023. Details are as follows:
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market
Seeking Alpha
21 апр 2023 г. в 16:46
Spero Therapeutics: Massive Partnership Deal Still Not Properly Valued By The Market.